<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687255</url>
  </required_header>
  <id_info>
    <org_study_id>AT-301</org_study_id>
    <nct_id>NCT03687255</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allecra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allecra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, randomized, double-blind, non-inferiority study of cefepime 2 g/AAI101 500 mg&#xD;
      combination compared to piperacillin 4 g/tazobactam 500 mg in a population of adult patients&#xD;
      with cUTI or AP. The study will be conducted in approximately 115 sites located in the EU,&#xD;
      the US, Central, South America and South Africa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">February 15, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in the Microbiological Modified Intent to Treat (m-MITT) Population who achieve overall treatment success at Test Of Cure (TOC)</measure>
    <time_frame>7 days after EOT [±2 days] for patients receiving 7 days of treatment and 19 days after randomization [±2 days] for patients receiving more than 7 days of treatment.</time_frame>
    <description>Treatment success is defined as the composite of clinical outcome of Cure and the microbiological outcome of Eradication (&lt;103 CFU/mL in urine culture).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the m-MITT Population with overall treatment success at End of Treatment (EOT)</measure>
    <time_frame>7 days for patients with cUTI only and up to 14 days for patients cUTI and blood stream infections</time_frame>
    <description>Treatment success is defined as the composite of clinical outcome of Cure and the microbiological outcome of Eradication (&lt;103 CFU/mL in urine culture).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1043</enrollment>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>cefepime/AAI101 combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefepime 2 g in combination with AAI101 500 mg q8h (2 hour infusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piperacillin 4 g in combination with Tazobactan 500 mg q8h (2 hour infusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime/AAI101 combination</intervention_name>
    <description>cefepime 2 g / AAI101 500 mg</description>
    <arm_group_label>cefepime/AAI101 combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/tazobactam</intervention_name>
    <description>piperacillin 4 GM / tazobactam 500 MG</description>
    <arm_group_label>piperacillin/tazobactam</arm_group_label>
    <other_name>PIP/TAZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Male or female patients &gt;18 years of age at the time of signing of informed consent;&#xD;
&#xD;
          2. Expectation that the patient's cUTI or AP will require hospitalisation and initial&#xD;
             treatment with at least 7 days of intravenous (i.v.) antibiotics;&#xD;
&#xD;
          3. Female patients who are no longer of childbearing potential&#xD;
&#xD;
          4. Female patients of childbearing potential must have a negative urine and/or serum&#xD;
             pregnancy test (serum β-human chorionic gonadotropin) within 1 day prior to study&#xD;
             entry;&#xD;
&#xD;
          5. Male patients, female patients receiving hormone replacement therapy (HRT), and female&#xD;
             patients of childbearing potential must agree to use highly effective contraception&#xD;
             methods&#xD;
&#xD;
          6. Pyuria, defined as: a. White blood cell count &gt;10 cells/mm3 in unspun urine or ≥10&#xD;
             cells/high power field in spun urine sediment; or b. Urinalysis/dipstick analysis&#xD;
             positive for leukocyte esterase;&#xD;
&#xD;
          7. Clinical signs and/or symptoms of cUTI or AP&#xD;
&#xD;
          8. Have a baseline urine culture specimen obtained within 48 hours prior to randomization&#xD;
&#xD;
          9. Expectation, in the judgment of the Investigator, that any implanted urinary&#xD;
             instrumentation (e.g., nephrostomy tubes, ureteric stents, etc.) will be surgically&#xD;
             removed or replaced before or within 24 hours after randomisation, unless removal or&#xD;
             replacement is considered unsafe or contraindicated.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Known urine culture with Gram-positive primary pathogen at ≥105 colony-forming units&#xD;
             (CFU)/mL (not contaminant) or suspected Gram-positive pathogen by Gram staining (Note:&#xD;
             Gram staining is optional);&#xD;
&#xD;
          2. History of significant hypersensitivity or allergic reaction to cefepime,&#xD;
             piperacillin/tazobactam, any of the excipients used in the respective formulations,&#xD;
             any beta-lactam antibiotics (e.g., cephalosporins, penicillins, carbapenems, or&#xD;
             monobactams), or any beta-lactamase inhibitors (e.g., tazobactam, sulbactam, or&#xD;
             clavulanic acid);&#xD;
&#xD;
          3. In the opinion of the Investigator, the patient is considered unlikely to survive the&#xD;
             approximately 6-week study period;&#xD;
&#xD;
          4. Weight &gt;180 kg;&#xD;
&#xD;
          5. Concurrent infection that would interfere with evaluation of response to the study&#xD;
             antibiotics;&#xD;
&#xD;
          6. Need for or receipt of concomitant systemic antimicrobial agents after signing of&#xD;
             informed consent, in addition to those designated in the study-treatment groups, with&#xD;
             the exception of a single oral dose of any antifungal treatment for vaginal&#xD;
             candidiasis;&#xD;
&#xD;
          7. Receipt of potentially effective systemic antibacterial therapy for a continuous&#xD;
             duration of &gt; 24 hours during the previous 72 hours before the study-qualifying&#xD;
             baseline urine is obtained;&#xD;
&#xD;
          8. Complicated urinary tract infection (UTI) known at study entry to be caused by&#xD;
             pathogens resistant to the study antibiotics;&#xD;
&#xD;
          9. Likely to require the use of an antibiotic for cUTI or AP prophylaxis during the&#xD;
             patient's participation in the study;&#xD;
&#xD;
         10. Intractable UTI at baseline that the Investigator anticipates would require &gt;14 days&#xD;
             of study drug therapy;&#xD;
&#xD;
         11. Complete, permanent obstruction of the urinary tract that is not anticipated to be&#xD;
             medically or surgically relieved during i.v. study therapy and before End of Treatment&#xD;
             (EOT);&#xD;
&#xD;
         12. Gross hematuria requiring intervention other than administration of study drug or&#xD;
             removal or exchange of a urinary catheter;&#xD;
&#xD;
         13. Presence of any known or suspected disease or condition that, in the opinion of the&#xD;
             Investigator, may confound the assessment of efficacy.&#xD;
&#xD;
         14. Suspected or confirmed acute bacterial prostatitis, orchitis, epididymitis, or chronic&#xD;
             bacterial prostatitis as determined by history and/or physical examination;&#xD;
&#xD;
         15. Impairment of renal function with estimated glomerular filtration rate &lt;30 mL/min/1.73&#xD;
             m2 calculated by the 4-variable Modification of Diet in Renal Disease study equation,&#xD;
&#xD;
         16. Urinary tract surgery within 7 days prior to randomisation or urinary tract surgery&#xD;
             planned during the study period (except surgery required to relieve an obstruction or&#xD;
             place a stent or nephrostomy prior to EOT);&#xD;
&#xD;
         17. Any condition or circumstance that, in the opinion of the Investigator, would&#xD;
             compromise the safety of the patient or the quality of study data;&#xD;
&#xD;
         18. Any rapidly progressing disease or immediately life-threatening illness, including&#xD;
             acute hepatic failure and respiratory failure;&#xD;
&#xD;
         19. Presence of sepsis, producing life-threatening organ dysfunction&#xD;
&#xD;
         20. A QT interval corrected using Fridericia's formula &gt;450 msec;&#xD;
&#xD;
         21. Immunocompromising condition, including known history of acquired immune deficiency&#xD;
             syndrome or known recent CD4 count &lt;200/mm3, hematological malignancy, or bone marrow&#xD;
             transplantation; or immunosuppressive therapy including cancer chemotherapy,&#xD;
             medications for prevention of organ transplantation rejection, or the administration&#xD;
             of corticosteroids ≥20 mg of prednisone or equivalent per day administered&#xD;
             continuously for &gt;14 days prior to randomisation;&#xD;
&#xD;
         22. One or more of the following laboratory abnormalities in baseline specimens obtained&#xD;
             at Screening: aspartate aminotransferase, alanine aminotransferase, alkaline&#xD;
             phosphatase, or total bilirubin level &gt;3 × upper limit of normal, or current&#xD;
             clinically significant liver disease, including any form of known liver cirrhosis;&#xD;
&#xD;
         23. One or more of the following laboratory abnormalities at Screening: platelet count&#xD;
             &lt;50,000/μL, absolute neutrophil count &lt;1,000/mm3, or hemoglobin &lt;8 g/dL;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Josephs Clinical Research</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southbay Pharma Research</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Urology Partners</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIGA Dr Ramon Carrillo</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1706FWM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brest Regional Hospital</name>
      <address>
        <city>Brest</city>
        <zip>224027</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Rahila Angelova AD, Pernik</name>
      <address>
        <city>Pernik</city>
        <zip>2300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital for Infectious Diseases &quot;Dr. Fran Mihaljevic&quot; Department for general infectious diseases</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unimed Adjara - Kutaisi oncological centre</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bugat Pal Korhaz</name>
      <address>
        <city>Gyöngyös</city>
        <zip>3200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uroklinika, LLC</name>
      <address>
        <city>Riga</city>
        <zip>LV-1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Siauliai caunty hospital</name>
      <address>
        <city>Šiauliai</city>
        <zip>76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Especializado en Investigación Clínica S.C.</name>
      <address>
        <city>Boca Del Río</city>
        <zip>CP. 94290</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Internacional - Sede San Borja</name>
      <address>
        <city>Lima</city>
        <zip>15036</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Klinika Chorob Wewnetrznych, Nefrologii i Transplantologii</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Center Eco-Safety</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interne oddelenie, Nemocnica Malacky, Nemocnicna a.s.</name>
      <address>
        <city>Malacky</city>
        <zip>90122</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Projects Research</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar, Department of Infectious Disease</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chernihiv City Hospital #2 of Chernihiv City Council, department of Urology</name>
      <address>
        <city>Chernihiv</city>
        <zip>14034</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 26, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
    <mesh_term>Enmetazobactam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>April 13, 2021</submitted>
    <returned>May 5, 2021</returned>
    <submitted>May 5, 2021</submitted>
    <returned>May 26, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

